CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
Dosage
100-300 mcg each combined subcutaneous 1-3x daily
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Synergistic GH Release
Dual-pathway activation produces 3-5x greater GH pulses than either peptide alone.
Body Composition
Improved lean mass, reduced fat, and better recovery.
Mechanism of Action
The CJC-1295 + Ipamorelin combination exploits the synergistic interaction between two distinct signaling pathways on pituitary somatotroph cells. CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, a Gs-coupled GPCR that stimulates adenylyl cyclase, raising intracellular cAMP and activating PKA. Ipamorelin activates the ghrelin/GHS-R1a receptor, a Gq/11-coupled GPCR that stimulates phospholipase C, generating IP3 and DAG, raising intracellular calcium and activating protein kinase C.
These two pathways converge on the final common pathway of GH vesicle exocytosis but through complementary mechanisms. cAMP/PKA signaling (from CJC-1295) primes GH gene transcription and vesicle loading, while calcium/PKC signaling (from Ipamorelin) triggers the actual calcium-dependent exocytosis of GH-containing secretory granules. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than what either peptide produces alone — studies suggest the combined GH output can be 3-5 times greater than either agent in isolation.
Additionally, Ipamorelin's hypothalamic effects complement CJC-1295's direct pituitary action. At the hypothalamic level, ghrelin receptor agonists suppress somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This creates a permissive window during which CJC-1295's GHRH-like stimulation of somatotrophs is maximally effective. Importantly, both peptides preserve the natural pulsatile pattern of GH release — somatostatin feedback still operates between pulses, maintaining the physiological pulse spacing that is important for target tissue sensitivity. The combination's selectivity profile is also favorable: Ipamorelin's selectivity avoids the cortisol and prolactin elevation seen with older GHRPs, while CJC-1295's 30-minute half-life avoids the sustained GH elevation of the DAC version. This makes CJC/Ipa the most widely prescribed GH peptide stack in anti-aging medicine.
Regulatory Status
Not FDA approved as a combination. Both components available through compounding pharmacies and peptide clinics. Among the most widely prescribed peptide stacks in anti-aging medicine.
Risks & Safety
Common
facial flushing, headache, dizziness, injection site irritation, temporary water retention.
Serious
may promote growth of existing tumors (growth hormone raises IGF-1 levels).
Rare
allergic reactions, significant swelling.
Compare CJC-1295 + Ipamorelin With
Research Papers
2Published: December 31, 2025
AI Summary
A broad review explains how growth hormone secretagogues like CJC-1295 and ipamorelin support tissue repair, inflammation control, and nerve recovery in musculoskeletal care. While animal studies look promising, human clinical trials are still lacking.
Published: December 31, 2025
AI Summary
A primer for orthopaedic surgeons on injectable therapeutic peptides, given the growing market and patient interest. The paper emphasizes the need to understand current evidence before recommending these compounds.
Frequently Asked Questions
What is CJC-1295 + Ipamorelin?
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
What is CJC-1295 + Ipamorelin used for?
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
What is the dosage for CJC-1295 + Ipamorelin?
Standard: 100-300 mcg of each peptide combined in a single subcutaneous injection, once to three times daily (most commonly before bed). Cycled 5 days on, 2 days off, or continuously for 8-12 weeks.
What are the side effects of CJC-1295 + Ipamorelin?
Common: facial flushing, headache, dizziness, injection site irritation, temporary water retention. Serious: may promote growth of existing tumors (growth hormone raises IGF-1 levels). Rare: allergic reactions, significant swelling.
How does CJC-1295 + Ipamorelin work?
The CJC-1295 + Ipamorelin combination exploits the synergistic interaction between two distinct signaling pathways on pituitary somatotroph cells. CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, a Gs-coupled GPCR that stimulates adenylyl cyclase, raising intracellular cAMP and activating PKA. Ipamorelin activates the ghrelin/GHS-R1a receptor, a Gq/11-coupled GPCR that stimulates phospholipase C, generating IP3 and DAG, raising intracellular calcium and activating protein kinase C. These two pathways converge on the final common pathway of GH vesicle exocytosis but through complementary mechanisms. cAMP/PKA signaling (from CJC-1295) primes GH gene transcription and vesicle loading, while calcium/PKC signaling (from Ipamorelin) triggers the actual calcium-dependent exocytosis of GH-containing secretory granules. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than what either peptide produces alone — studies suggest the combined GH output can be 3-5 times greater than either agent in isolation. Additionally, Ipamorelin's hypothalamic effects complement CJC-1295's direct pituitary action. At the hypothalamic level, ghrelin receptor agonists suppress somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This creates a permissive window during which CJC-1295's GHRH-like stimulation of somatotrophs is maximally effective. Importantly, both peptides preserve the natural pulsatile pattern of GH release — somatostatin feedback still operates between pulses, maintaining the physiological pulse spacing that is important for target tissue sensitivity. The combination's selectivity profile is also favorable: Ipamorelin's selectivity avoids the cortisol and prolactin elevation seen with older GHRPs, while CJC-1295's 30-minute half-life avoids the sustained GH elevation of the DAC version. This makes CJC/Ipa the most widely prescribed GH peptide stack in anti-aging medicine.
How is CJC-1295 + Ipamorelin administered?
CJC-1295 + Ipamorelin is administered via subcutaneous injection.
What is the half-life of CJC-1295 + Ipamorelin?
The half-life of CJC-1295 + Ipamorelin is CJC-1295: 0.5 hours | Ipamorelin: 2 hours.
Is CJC-1295 + Ipamorelin legal?
Not FDA approved as a combination. Both components available through compounding pharmacies and peptide clinics. Among the most widely prescribed peptide stacks in anti-aging medicine.
Related Peptides
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.